Recurrent Glioblastoma Multiforme May Be Improved by Immunotherapy Treatment

In a recent study, researchers investigated the safety and efficacy of a vaccine called heat-shock protein peptide complex-96 (HSPPC-96) for patients with recurrent glioblastoma multiforme (GBM), a common brain malignancy with a universally poor prognosis. Immunotherapy treatment offers the promise of improved outcomes for patients with GBM by providing a nontoxic alternative to conventional treatment options such as chemotherapy. To read more about the results of this research, click here.